



STATES PROPERTY STATES

MICROCOPY RESOLUTION TEST CHART



TRYPANOSOME SURFACE ANTIGEN GENES:

ANALYSIS USING RECOMBINANT DNA

FINAL REPORT

12/1/81 - 8/31/84

Kenneth D. Stuart, Ph.D.

March 27, 1985



Supported by

U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-82-C-2016

Issaquah Health Research Institute '1595 N.W. Gilman Blvd.
Issaquah, Washington 98027

DOD DISTRIBUTION STATEMENT

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized document.

DING FILE COP

18. REPORT SECURITY CLASSIFICATION Unclassified 28. SECURITY CLASSIFICATION AUTHORITY 28. DECLASSIFICATION AUTHORITY 28. DECLASSIFICATION AUTHORITY 29. DECLASSIFICATION AUTHORITY 29. DECLASSIFICATION AUTHORITY 20. DECLASSIFICATION AUTHORITY 20. DECLASSIFICATION AUTHORITY 20. DECLASSIFICATION AUTHORITY 20. DECLASSIFICATION AUTHORITY 21. Approved for public release; Distribution unlimited 22. MADRESS (CRY, State, and ZIP Code) 23. NAME OF PERFORMING ORGANIZATION 24. NAME OF MONITORING ORGANIZATION 25. NAME OF MONITORING ORGANIZATION 26. ADDRESS (CRY, State, and ZIP Code) 27. NAME OF MONITORING ORGANIZATION 28. NAME OF FUNDING (SPONSORING ORGANIZATION) 29. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER 29. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER 20. SOURCE OF FUNDING NUMBERS 21. TITLE (Include Security Classification) 22. PROSONAL AUTHOR(S) 23. TYPE OF REPORT 24. DATE OF REPORT (Year, Month, Day) 25. PAGE COUNT 26. SUPPLEMENTARY NOTATION 27. COSATI CODES 28. SUBJECT TERMS (Continue on reverse if necessary and identify by block number 27. FIRST (Continue on reverse if necessary and identify by block number 27. COSATI CODES 28. SUBJECT TERMS (Continue on reverse if necessary and identify by block number 29. STATE OF THE ORGANIZATION 29. STATE ORGANIZATION 29. PROCUREMENT INSTRUMENT IDENTIFICATION 29. PROCUREMENT INSTRUMENT IDENTIFICATION 29. PROCUREMENT INSTRUMENT IDENTIFICATION 29. PROCUREMENT INSTRUMENT IDENTIFICATION 29. PROC	SECURITY CLASSIFICATION OF	THIS PAGE	REPORT DOCU	MENTATION	DAGE		
28. SECURITY CLASSIFICATION AUTHORITY 2b. DECLASSIFICATION / DOWNGRADING SCHEDULE 2c. DECLASSIFICATION / DOWNGRADING SCHEDULE 2c. DESCRIPTION / DOWNGRADING SCHEDULE 2c. NAME OF PERFORMING ORGANIZATION INSURED (If applicable) 2c. NAME OF PERFORMING ORGANIZATION INSURED (If applicable) 2c. NAME OF PERFORMING ORGANIZATION INSURED (If applicable) 2c. ADDRESS (City, State, and ZIP Code) 2c. NAME OF FUNDING / SPONSORING ORGANIZATION INSURED (If applicable) 2c. ADDRESS (City, State, and ZIP Code) 2c. NAME OF FUNDING / SPONSORING ORGANIZATION INSURED (If applicable) 2c. ADDRESS (City, State, and ZIP Code) 2c. ADDRESS (City, State, and ZIP C	1a REPORT SECURITY CLASSI	IFICATION	REPORT DOCO				
Approved for public release; Distribution unlimited A PERFORMING ORGANIZATION REPORT NUMBER(S) 5. MONITORING ORGANIZATION REPORT NUMBER(S) 7. NAME OF PERFORMING ORGANIZATION I Sasquah Health Research Institute 6. ADDRESS (City, State, and ZIP Code) TSSaquah, Washington 98027 8. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medic al. (If applicable) Research & Development Comband 8. ADDRESS (City, State, and ZIP Code) 7. DADDRESS (City, State, and ZIP Code) 8. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medic al. (If applicable) Research & Development Comband 8. ADDRESS (City, State, and ZIP Code) 7. DADDRESS (City, State, an							
2b. Declassification/Downgrading Schedule 4. Performing Organization Report Number(s) 5. Monitoring Organization Report Number(s) 6a. Name of Performing Organization Issaquah Health Research Institute 6c. Address (Criv, State, and ZIP Code) 1595 N.W. Gilman Blvd. Issaquah, Washington 98027 8a. Name of Funding/Sponsoring Organization U.S. Army Medical (if applicable) Research & Development Command 8c. Address (Criv, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 10. Source of Funding Numbers PROGRAM Frederick, Maryland 21701-5012 11. Title (Include Security Classification) Trypanosome Surface Antigen Genes; Analysis Using Recombinant DNA. 12. Personal Author(s) Kenneth D. Stuart, Ph.D. 13a. Type of Report Fromby 1/1/12 to 84/31/8 14. Date of Report (Year, Month, Day) Fromby 1/1/12 to 84/31/8 15. Page Count 16. Supplementary Notation 17. COSATI CODES FIELD GROUP SUB-GROUP 06 03 06 13	2a. SECURITY CLASSIFICATION	N AUTHORITY					e:
6s. NAME OF PERFORMING ORGANIZATION I Saaquah Health Research Institute 6c. ADDRESS (City, State, and ZIP Code) 1595 N.W. Gilman Blvd. Issaquah, Washington 98027 8s. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical (If applicable) Research & Development Command 8c. ADDRESS (City, State, and ZIP Code) Research & Development Command 8c. ADDRESS (City, State, and ZIP Code) Research & Development Command 8c. ADDRESS (City, State, and ZIP Code) Research & Development Command 8c. ADDRESS (City, State, and ZIP Code) Research & Development Command 8c. ADDRESS (City, State, and ZIP Code) Research & Development Command 10. SOURCE OF FUNDING NUMBERS 8c. ADDRESS (City, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS 11. TITLE (Include Security Classification) 12. PERSONAL AUTHOR(S) 13. TYPE OF REPORT FINAL Report 13. TIME COVERED FROM 13. TIME COVERED FROM 1/1/12 TO 84/31/8 13. TYPE OF REPORT FINAL Report 13. TIME COVERED FROM 1/1/12 TO 84/31/8 14. DATE OF REPORT (Yeer, Month, Day) 15. PAGE COUNT 1/2 16. SUPPLEMENTARY NOTATION 17. NAME OF MONITORING ORGANIZATION 75. ADDRESS (City, State, and ZIP Code) 9. PROCUREMENT INSTRUMENT I	2b. DECLASSIFICATION / DOW	NGRADING SCHEDU	LE				, ,
Issaquah Health Research Institute 6. ADDRESS (City, State, and ZIP Code) 1595 N.W. Gilman Blvd. Issaquah, Washington 98027 8. NAME OF FUNDING/SPONSORING Medical (If applicable) Research & Development Command 8. ADDRESS (City, State, and ZIP Code) Research & Development Command 8. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. NO. 3M1627704 B70 AH OCC STATE OF ST	4. PERFORMING ORGANIZATI	ION REPORT NUMBE	R(S)	5. MONITORING	ORGANIZATION RE	PORT NUMBER	(S)
1595 N.W. Gilman Blvd. Issaquah, Washington 98027 8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical (If applicable) Research & Development Command 8c. ADDRESS (City, State, and ZIPCode) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT NASK ACCESSM ELEMENT NO. 62770A 11. TITLE (Include Security Classification) Trypanosome Surface Antigen Genes; Analysis Using Recombinant DNA. 12. PERSONAL AUTHOR(S) Kenneth D. Stuart, Ph.D. 13a. TYPE OF REPORT 13b. TIME COVERED FROMEN 1/1/12 to 84/31/8 15. PAGE COUNT 12 to 84/31/8 16. SUPPLEMENTARY NOTATION 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number field GROUP SUB-GROUP O6 03 03 06 13	Issaquah Health			7a. NAME OF M	ONITORING ORGAN	IZATION	 -
Research & Development Command 8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 62770A 870 AH OCCESS 62770A 3M162770A870 AH OCCE	1595 N.W. Gilma	an Blvd.	27	7b. ADDRESS (Cit	ty, State, and ZIP C	ode)	
Research & Development Command 8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 62770A 870 AH 11. TITLE (Include Security Classification) Trypanosome Surface Antigen Genes; Analysis Using Recombinant DNA. 12. PERSONAL AUTHOR(S) Kenneth D. Stuart, Ph.D. 13a. TYPE OF REPORT 13b. TIME COVERED FRONB1/1/12 to 84/31/8 14. DATE OF REPORT (Year, Month, Day) Final Report 13b. TIME COVERED FRONB1/1/12 to 84/31/8 16. SUPPLEMENTARY NOTATION 17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number 196 03 03 06 13	8a. NAME OF FUNDING/SPO	NSORING M	8p. OFFICE SYMBOL	9. PROCUREMEN	T INSTRUMENT IDE	NTIFICATION N	UMBER
8c. ADDRESS (City, State, and ZiP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 62770A B70 AH OCCESSM				DAMD17-8	2 - C-2016		
Frederick, Maryland 21701-5012 Cosati Codes Field Group Sub-group Group G			L				
Trypanosome Surface Antigen Genes; Analysis Using Recombinant DNA. 12. PERSONAL AUTHOR(S) Kenneth D. Stuart, Ph.D. 13a. TYPE OF REPORT Final Report Final Report 16. SUPPLEMENTARY NOTATION 17. COSATI CODES FIELD GROUP SUB-GROUP O6 03 O6 13		yland 21701	- 5012	ELEMENT NO.	NO.	NO.	WORK U
17. COSATI CODES FIELD GROUP SUB-GROUP O6 03 O6 13	12. PERSONAL AUTHOR(S)	Kenneth D	. Stuart, Ph	.D.			
FIELD GROUP SUB-GROUP 06 03 06 13	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report	Kenneth D	Stuart, Ph	.D.	DRT (Year, Month, D		COUNT
06	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report	Kenneth D	Stuart, Ph	.D.	DRT (Year, Month, D		COUNT
06 13	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT	Kenneth D 13b. Time Co FROMB1/	o. Stuart, Ph overed 1/12 to 84/31/	D. 14. DATE OF REPORT 198	ort (Year, Month, 0 5 March 27	lay) 15. PAGE	E COUNT 12
	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI (FIELD GROUP	Kenneth D 13b. Time Co FROMB1/	o. Stuart, Ph overed 1/12 to 84/31/	D. 14. DATE OF REPORT 198	ort (Year, Month, 0 5 March 27	lay) 15. PAGE	E COUNT 12
	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI (FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on a	Kenneth D 13b. TIME CO FROMB1/ TION CODES SUB-GROUP reverse if necessary	Stuart, Phovered 1/12 to 84/31/	.D. 14. DATE OF REPORT 198 (Continue on revers	ort (Year, Month, D 5 March 27 March 27	identify by blo	E COUNT 12 ock number
The objective of this project is to identify and isolate early	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI (FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on a	Kenneth D 13b. TIME COFROMB1/ TION CODES SUB-GROUP reverse if necessary tive of thi	Stuart, Ph OVERED 1/12 TO 84/31/ 18. SUBJECT TERMS and identify by block s project is	.D. 14. DATE OF REPORT 198 (Continue on reverse number) to identi	ort (Year, Month, D 5 March 27 be if necessary and fy and iso	identify by blo	count 12 12 12 12 12 12 12 12 12 12 12 12 12
(frequently expressed) variant antigenic types (VATs), and clone	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI (FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on a continue on a conti	Kenneth D 13b. TIME COFROMB1/ TION CODES SUB-GROUP reverse if necessary tive of thi xpressed) v	Stuart, Phovered 1/12 to 84/31/ 18. SUBJECT TERMS and identify by block as project is rariant antig	.D. 14. DATE OF REPO 198 (Continue on reverse on mumber) to identienic types	fy and iso	identify by blo	count 12
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted,	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATION FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on the object of the object of the content of the conte	Kenneth D 13b. TIME CO FROMB1/ TION CODES SUB-GROUP tive of thi xpressed) v ize their e ous syringe	Stuart, Phovered 1/12 TO 84/31/ 18. SUBJECT TERMS and identify by block are project is expressed vare passaged and	D. 14. DATE OF REPO 198 (Continue on reversional to idential enic types iant surfade cyclical	fy and iso (VATs), as ce glycoproly transmi	identify by blo	e count 12 ock number
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted, frequently expressed VATs have been isolated, monoclonal antibodies	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on the object of the continue on the continue	Kenneth D 13b. TIME CO FROMB1/ TION CODES SUB-GROUP tive of thi xpressed) v ize their e ous syringe pressed VAT	Stuart, Phovered 1/12 TO 84/31/ 18. SUBJECT TERMS and identify by block as project is rariant antig expressed var passaged and shave been	.D. 14. DATE OF REPO 198 (Continue on reversion to idential enic types iant surfact cyclical isolated, i	fy and iso (VATs), as ce glycoprimonoclonal	identify by bloom late earnd clone otein (Vtted, antibod	e count 12 ock number 1y SG)
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted, frequently expressed VATs have been isolated, monoclonal antibodies prepared to their VSGs, and the expressed VSG genes have been cloned. We have shown that many diverse stocks express VSG epitopes related	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on the continue on the contin	Kenneth D 13b. TIME CO FROM 81/ TION CODES SUB-GROUP tive of thi xpressed) v ize their e ous syringe pressed VAT heir VSGs, that many	stuart, Phovered 1/12 TO 84/31/ 18. SUBJECT TERMS and identify by block s project is ariant antig expressed var passaged and shave been and the expressed varies and the expressed stock.	Continue on revenue to identienic types iant surfad cyclical isolated, essed VSG ks express	fy and isometry transminus transminus and isometry transminus and isomet	late earnd clone otein (V tted, antibod been cl	e count 12 12 12 13 12 13 12 13 13 14 15 16 16 16 16 16 16 16 16 16 16 16 16 16
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted, frequently expressed VATs have been isolated, monoclonal antibodies prepared to their VSGs, and the expressed VSG genes have been cloned. We have shown that many diverse stocks express VSG epitopes related to the early IsTat epitopes. The VSG gene organization has been	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATION FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on the object of the quently example of the continue on the continue on the have shown to the early in the continue on the	Kenneth D 13b. TIME CO FROM 81/ TION CODES SUB-GROUP tive of thi xpressed) v ize their e ous syringe pressed VAT heir VSGs, that many IsTat epito	stuart, Phovered 1/12 TO 84/31/ 18. SUBJECT TERMS and identify by block s project is expressed var expressed var expressed var s have been and the expressed vare. The VS	Continue on revenue to identienic types iant surfad cyclical isolated, essed VSG ks express G gene organical cyclical continue on revenue to identify the cyclical cy	fy and iso (VATs), and ce glycoprimonoclonal genes have VSG epitomanization	late earnd clone otein (Vtted, antibod been clues relahas been	ely ies oned.
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted, frequently expressed VATs have been isolated, monoclonal antibodies prepared to their VSGs, and the expressed VSG genes have been cloned. We have shown that many diverse stocks express VSG epitopes related to the early IsTat epitopes. The VSG gene organization has been characterized. We have confirmed sequence homology at the 3' terminus	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATIO FIELD GROUP 06 03 06 13 19. ABSTRACT (Continue on all the object of the continue on all the object of the continue on all the continue on all the object of the obje	Kenneth D 13b. TIME COFROMB 1/2 TION CODES SUB-GROUP tive of thi xpressed) vize their eous syringe pressed VAT heir VSGs, that many IsTat epito. We have	stuart, Phovered 1/12 to 84/31/ 18. SUBJECT TERMS and identify by block sproject is ariant antig expressed var passaged and shave been and the expression and the expression of the VS confirmed se	number) to identient types iant surfad cyclical isolated, essed VSG ks express G gene organical cyclical isolated.	fy and iso (VATs), as ce glycopromonoclonal genes have VSG epitomology at the second s	late earnd clone otein (Vtted, antibod been clpes relahas been he 3' te	ck number 12 SG) ies oned. ted
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted, frequently expressed VATs have been isolated, monoclonal antibodies prepared to their VSGs, and the expressed VSG genes have been cloned. We have shown that many diverse stocks express VSG epitopes related to the early IsTat epitopes. The VSG gene organization has been characterized. We have confirmed sequence homology at the 3' terminus of the VSG genes and have discovered additional homology near the 5' terminus of unrelated VSG genes. Numerous relapse VATs have also been	13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI OF SUPPLEMENTARY NOTATION 18. OG 03 19. ABSTRACT (Continue on a characterizens. Numero frequently expenses. Numero frequently expenses to the have shown to the early characterized of the VSG genterminus of unitarial control of the VSG genterminus of unitaria	Kenneth D 13b. TIME OF FROMB1/ TION CODES SUB-GROUP tive of thi xpressed) vize their e ous syringe pressed VAT heir VSGs, that many IsTat epito We have nes and have nrelated VS	and identify by block s project is ariant antig expressed var passaged and the expression	number) to identient types iant surfad cyclical isolated, essed VSG ks express G gene organizational merous relations relations.	fy and iso (VATs), as ce glycoprimonoclonal genes have VSG epitomology at the company of the company of the company and the company at the co	late earnd clone otein (V tted, antibod been clapes relahas been he 3' te near the have als	Ty SG) ies oned. ted rminus e 5' o been
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted, frequently expressed VATs have been isolated, monoclonal antibodies prepared to their VSGs, and the expressed VSG genes have been cloned. We have shown that many diverse stocks express VSG epitopes related to the early IsTat epitopes. The VSG gene organization has been characterized. We have confirmed sequence homology at the 3' terminus of the VSG genes and have discovered additional homology near the 5'	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI OF GROUP 18. OG 03 19. ABSTRACT (Continue on a characterized of the VSG genterminus of units)	Kenneth D 13b. TIME OF FROMB1/ TION CODES SUB-GROUP tive of thi xpressed) vize their e ous syringe pressed VAT heir VSGs, that many IsTat epito We have nes and have nrelated VS	and identify by block s project is ariant antig expressed var passaged and the expression	number) to identient types iant surfad cyclical isolated, essed VSG ks express G gene organizational merous relations relations.	fy and iso (VATs), as ce glycoprimonoclonal genes have VSG epitomology at the company of the company of the company and the company at the co	late earnd clone otein (V tted, antibod been clapes relahas been he 3' te near the have als	Ty SG) ies oned. ted rminus e 5' o been
(frequently expressed) variant antigenic types (VATs), and clone and characterize their expressed variant surface glycoprotein (VSG) genes. Numerous syringe passaged and cyclically transmitted, frequently expressed VATs have been isolated, monoclonal antibodies prepared to their VSGs, and the expressed VSG genes have been cloned. We have shown that many diverse stocks express VSG epitopes related to the early IsTat epitopes. The VSG gene organization has been characterized. We have confirmed sequence homology at the 3' terminus of the VSG genes and have discovered additional homology near the 5' terminus of unrelated VSG genes. Numerous relapse VATs have also been	12. PERSONAL AUTHOR(S) 13a. TYPE OF REPORT Final Report 16. SUPPLEMENTARY NOTAT 17. COSATI OF GROUP 06 03 06 13 19. ABSTRACT (Continue on a characterized of the VSG genterminus of unisolated and color of the vsc genterminus of unisolated and color of the	Kenneth D 13b. TIME OF FROMB1/ TION CODES SUB-GROUP reverse if necessary tive of this pressed varinge pressed varinge pressed varinge pressed variate epito We have nessed have nessed have nessed variated	stuart, Phovered 1/12 to 84/31/ 18. SUBJECT TERMS and identify by block s project is ariant antig expressed var passaged and the expression of the view of the	number) to identient types iant surfad cyclical isolated, essed VSG ks express G gene organizational merous relect to tele	fy and iso (VATs), as ce glycoprimonoclonal genes have VSG epitoranization ology at the homology apse VATs omeric local	late earnd clone otein (V tted, antibod been clapes relahas been he 3' te near th have als ation of	Ty SG) ies oned. ted rminus e 5' o been

genes and duplicative or non-duplicative mode of VSG gene expression. We have found that two fundamental processes control the expression of VSG genes. One involves gene duplication; the other telomeric activation. In addition, the telomeric location of the gene affects its probability of expression and stability. DNA sequence analysis in and around flanking VSG genes has characterized some of the internal homology and identified flanking sequence homology blocks. The latter probably function in duplicative activation of VSG genes. Keywords.

SUMMARY

The purpose was to isolate and characterize early variant antigenic types (VATs) and the corresponding variant surface glycoprotein (VSG) genes of African trypanosomes.

METHODS

The VATs were isolated from chronic and relapse infections by cell cloning. The VSGs were purified from these VATs by affinity chromatography and used to produce VSG specific monoclonal antibodies. These antibodies were used to characterize VAT populations. VSG gene sequences were isolated by molecular cloning of cDNAs which were in turn used as probes to isolate VSG gene sequences cloned from genomic DNA. These cloned VSG gene sequences were characterized directly by restriction mapping and nucleotide sequence analysis and were used as probes to examine the organization and expression of the VSG genes and the process of antigenic variation.
RESULTS AND CONCLUSIONS

The VSG genes expressed by early VATs are located near telomeres of minichromosomes or larger chromosomes indicating that telomeric genes are preferentially expressed. Telomeric genes can be replaced by gene conversion showing that the repertoire is not stable. Several factors including VAT growth rate and switching frequency affect the sequence of VAT occurrence and the VAT composition of relapse populations. The IsTat 1 early VATs occur frequently in several stocks of African trypanosomes indicating that the antigen genes are conserved and expressed in several natural populations.

VSG genes conserve certain sequences in their 5 and 3 flanks and in their coding sequences. A V-sequence constitutes most of the barren region of telomeric VSG genes and occurs in the 5 flank of some, but not all, intrachromosomal VSG genes. This sequence occurs near the 5 boundary of gene conversion and may have a role in this process but it cannot yet be determined if it has a role in controlling VSG gene expression. Most, but not all, VSG genes also conserve a 3 sequence. All telomeric VSG genes conserve a more extensive sequence and also conserve a CCCTAA containing sequence that may be a characteristic of the telomere. Sequences are also conserved within the coding sequence. The 3 ends are similar among VSG genes and a sequence is conserved near the 5 end of the coding sequence. The conserved 3 end may function in associating the VSG to the cell membrane; the function of the 5 conserved region is not known.

The VSG genes exist as families of related sequences within chromosomes and near telomeres. The VSG genes are expressed at telomeres. Two processes mediate antigenic variation. One is a gene conversion mechanism that replaces one expressed VSG coding sequence with a copy of another. The second mechanism transcriptionally activates an alternate VSG gene and inactivates the former VSG gene. These processes are independent. In addition, transcripts of VSG genes are processed to remove 5' sequences; they also have a 35 nucleotide sequence spliced onto their 5' terminus. The addition of this 35 nucleotide sequence is a novel mechanism and is not restricted to VSG genes.

FOREWORD

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).

Accesion	For		
NTIS C DTIC To Unannou Justifica	AB 브		
By	tion /		
A	ailability Code	S	
Dist	Avail and or Special		
A-1			

TABLE OF CONTENTS

SECTION	PAGE
OBJECTIVES	5
PROGRESS REPORT	5
BIOLOGICAL	5
IMMUNOLOGICAL	6
MOLECULAR GENETIC	6
PUBLICATIONS	8

AD)	

TRYPANOSOME SURFACE ANTIGEN GENES: ANALYSIS USING RECOMBINANT DNA

FINAL REPORT

12/1/81 - 8/31/84

Kenneth D. Stuart, Ph.D.

CHARLES TO SECURE NOTIONS CONTROL STATES

March 27, 1985

Supported by

U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-82-C-2016

Issaquah Health Research Institute 1595 N.W. Gilman Blvd. Issaquah, Washington 98027

DOD DISTRIBUTION STATEMENT

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized document.

(1.) OBJECTIVES

The overall objective of this project was to investigate the characteristics of variant surface antigen (VSG) genes in African trypanosomes in order to determine if they had common characteristics that might be of value for immunoprophylaxis. This integrated biological/immunological/molecular genetic project had the following specific objectives for the period of support:

- 1.1 To identify and characterize frequently occurring and cyclically transmitted variant antigenic types (VATs). These experiments were designed to identify factors that are important to the frequent occurrence of VATs.
- 1.2 Examine the VSG genes of frequently occurring VATs to seek common characteristics within these genes to determine if they contain common sequences.
- 1.3 To characterize the flanking sequences of early and later VAT VSG genes. These experiments are designed to determine the molecular basis for the frequent expression of some VSG genes.
- 1.4 Determine the occurrence of IsTar 1 VATs among various stocks of African trypanosomes. These studies are designed to determine if particular epitopes are conserved among various stocks of trypanosomes.

(2.) PROGRESS REPORT

Since all of the results that are reported here have been reported on in detail in annual reports starting 12/1/81, 12/1/82, and 12/1/83, and in publications cited at the end of this report, this progress report will summarize the overall progress during the contract period.

(3.) BIOLOGICAL

We have produced a serodeme of antigenic variants from a clone of the EATRO 164 stock. This serodeme contains three general classes of variant antigenic types (VATs): l. various VATs occurring early or later during the course of a single infection. We have performed most of our studies with six VATs designated A, 1, 3, 5, 7, and 11 which were isolated in this order. 2. Relapses to the above six VATs which resulted from single antigenic switches. These VATs were useful since we knew the identity and characteristics of the VATs before and following an antigenic switch. 3. VATs that were isolated following cyclic transmission and VATs from other stocks that were immunologically cross reactive with the six VATs above.

Several biological parameters of these VATs were determined. These included the relative growth rates and VAT switching frequencies and the order of occurrence of the six VATs in first and subsequent relapses. We found that clones expressed VATs in characteristic orders but that this order could be modified as a

result of genomic rearrangement. These results show that while each serodeme expresses VATs in a characteristic order this order is not fixed but drifts. We also found that growth rate and switch frequencies were characteristic to each VAT and that these were important factors in the sequence of occurrence of VATs during an infection. Our molecular genetic studies suggest that the genomic location and the character of the flanking sequences affect expression frequency but we could not discern a basis for the differences in growth rates among VATs. These data taken together indicate that several factors influence the sequence of VAT occurrence and that the sequence undergoes spontaneous drift during the course of an infection.

(4.) IMMUNOLOGICAL

We have raised both monoclonal and polyclonal antibodies that are specific for the VSGs of the six VATs described above. These antibodies have been used to characterize the populations used for molecular studies and also for the studies of sequence of VAT occurrence. Most of the monoclonal antibodies did not react with the surface of live cells and did not cross react with different VSGs, but all reacted with isolated VSGs, or cell lysates in ELISA assays and with acetone fixed cs by immunofluorescence. Some, but not all, of the monoclonal antibodies reacted with in vitro translation products and with denatured proteins as determined by western blot experiments. These studies suggest that most of the antibodies are directed against polypeptide epitopes that are not exposed on the surface of live cells. Competitive immunofluorescence studies indicated that all monoclonal antibodies reacted with distinct epitopes.

(5.) MOLECULAR GENETIC

Several cDNAs were isolated for each of the six VATs that we studied. Taken together these cDNAs represented the entire coding sequence of most of these VSG genes. Each of these cDNAs has been characterized by restriction mapping and cross hybridization and the nucleotide sequence of many of the cDNAs has been determined. Some of the cDNAs contain a 35 nt sequence on their 5' terminus. This is the spliced leader (SL) sequence that occurs on the 5 terminus of all mRNAs in trypanosomes. Several of the cDNAs also have poly (A) tails indicating that they represent the 3' terminus of the coding sequence. We have found one region of cross hybridization among the cDNAs that is located a few hundred nucleotides from the 5' terminus but have not identified this region by sequencing. We have found conserved sequences within the 3' untranslated region of the sequence that has the character of CTCC, AT-rich, and a 123 mer that are conserved in this order. At least one of the cDNA clones expresses the VSG protein in E. coli and these studies showed that codon usage while employing several codons that are rarely used in coli did not prevent expression.

The cDNAs were used as probes to determine the number and organization of the VSG genes in the genome of VATs expressors

and non expressors of the corresponding VSGs. We found that there were 2, 0, 10, 3, 2, and 3 intrachromosomal members of the A, 1, 3, 5, 7, and 11, respectively, VSG gene families. In addition there were varying numbers of telomeric VSG genes depending on the particular clone of the VAT examined. Invariably, the gene that was expressed was located on a telomere. There were 1, 3, and 5 VAT VSG genes located on telomeres of minichromosomes. The 3 and 5 VSG genes served as basic copies for gene conversion leading to expression of the corresponding VAT. The minichromosomal 1 VSG gene was expressed without duplication on a minichromosome. The telomeric A VSG gene was located on an approximately 2000 kb chromosome. This gene could be expressed directly by telomeric activation or serve as a basic copy for the generation of another telomeric VSG gene. In addition the telomeric A gene could be lost leaving no telomeric A VSG genes.

The cDNAs were used as probes to isolate genomic clones that contained intrachromosomal VSG genes from lambda 1059 genomic libraries. They were also used as probes to clone the telomeric 1 VSG gene that was isolated from genomic DNA that had been treated with Bal 31 and a restriction enzyme. These genomic clones have been mapped in detail and the coding sequences have been located. Several segments of these genomic clones have been subcloned and used as probes and sequenced. These studies showed that many, but not all, intrachromosomal genes contained related, but not identical, sequences in their 5' and 3' flanks. The 5' flank contained a 76 nt sequence that occurred as a single sequence or as tandem repeats. This sequence often, but not always, contained a long sequence of TAA in tandem up to 109 times. The rest of the sequence had an alternating GT then alternating TA character. This sequence has the potential to be a B to Z transition region. This sequence occurred approximately at the 5' boundary of gene conversion and thus may be a recognition sequence for this event. The variation among these sequences may be a factor that contributes to the difference in switching frequencies among some The 3' flanking sequence also contained conserved sequences that varied among VATs. They were less extensive in size and less variable and had the CTCC, AT-rich then conserved 13 nt character. These sequences may represent the 3´ terminus of gene conversion. The VSG genes are clustered in tandem arrays in the genome but members of the same family are not in tandem.

The analyses of transcription have shown that VSG genes are transcribed as a larger precursor. However, the coding sequence contains no introns and all processing removes 5' sequences. However, all VSG (and other) mRNAs contain a 35 nt SL sequence on the 5' terminus that is transcribed from a large tandem array of a 1.4 kb sequence. The SL transcript is about 140 nt with the 35 nt sequence at its 5' terminus. The sequence from which the SL is transcribed is not cis to all VSG genes but the SL becomes spliced to the 5' end to the mRNA. The mechanism by which this occurs is unknown.

PUBLICATIONS

Milhausen, M., Nelson, R., Parsons, M., Newport, G., STUART, K. and Agabian, N. (1983). The IsTat l Serodeme of <u>Trypanosoma brucei</u>: Molecular Characterization of Initial Variants. Mol. Biochem. Parasitol., 9:241-254.

Parsons, M., Nelson, R.G., Newport, G., Milhausen, M., STUART, K. and Agabian, N. (1983). The IsTat 1 Variant Antigene Sequence Families: Genomic Organization in Sequential Parasitemias. Mol. Biochem. Parasitol. 9:255-269.

Parsons, M., Nelson, R., Agabian, N., and STUART, K. (1983). Genomic Organization of Variant Surface Glycoprotein Genes in <u>T. brucei</u> Procyclic Culture Forms, J. Cell. Biochem. 23:27-33.

Myler, P., Nelson, R.G., Agabian, N., and STUART, K. (1984). Two Mechanisms of Expression of a Predominant Variant Antigen Gene of Trypanosoma brucei. Nature. 309:282-284.

Myler, P., Allison, J., Agabian, N., and STUART, K. (1984). Antigenic Variation in African Trypanosomes by Gene Replacement or Activation of Alternate Telomeres. Cell 39:203-211.

Allison, J., Rothwell, V., Newport, G., Agabian, N., and STUART, K. (1984). The IsTat 1.3 VSG Gene Family in Trypanosoma brucei: Retention of the Expression Linked Copy Through Multiple Antigenic Switches. Nucleic Acids Res. 12:9051-9066.

Myler, P., Allen, A.L., Agabian, N., and STUART, K. (1985). Antigenic Variation in Clones of <u>Trypanosoma brucei</u> Grown in Immune-Deficient Mice. Inf. Immun. 47:684-690

DISTRIBUTION LIST

12 copies Director

Walter Reed Army Institute of Research

Walter Reed Army Medical Center

ATTN: SGRD-UWZ-C

Washington, DC 20307-5100

4 copies Commander

US Army Medical Research and Development Command

ATTN: SGRD-RMS

Fort Detrick, Frederick, Maryland 21701-5012

12 copies Defense Technical Information Center (DTIC)

ATTN: DTIC-DDAC Cameron Station

Alexandria, VA 22304-6145

1 copy Dean

School of Medicine

Uniformed Services University of the

Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799

1 copy Commandant

Academy of Health Sciences, US Army

ATTN: AHS-CDM

Fort Sam Houston, TX 78234-6100

EMED

5-86 DT [